TW202144007A - 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 - Google Patents

一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 Download PDF

Info

Publication number
TW202144007A
TW202144007A TW110112949A TW110112949A TW202144007A TW 202144007 A TW202144007 A TW 202144007A TW 110112949 A TW110112949 A TW 110112949A TW 110112949 A TW110112949 A TW 110112949A TW 202144007 A TW202144007 A TW 202144007A
Authority
TW
Taiwan
Prior art keywords
antibody
antigen
pharmaceutically acceptable
seq
acceptable salt
Prior art date
Application number
TW110112949A
Other languages
English (en)
Chinese (zh)
Inventor
鄒建軍
郭軍
Original Assignee
大陸商江蘇恆瑞醫藥股份有限公司
大陸商蘇州盛迪亞生物醫藥有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 大陸商江蘇恆瑞醫藥股份有限公司, 大陸商蘇州盛迪亞生物醫藥有限公司 filed Critical 大陸商江蘇恆瑞醫藥股份有限公司
Publication of TW202144007A publication Critical patent/TW202144007A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW110112949A 2020-04-10 2021-04-09 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途 TW202144007A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN202010278150.4 2020-04-10
CN202010278150 2020-04-10

Publications (1)

Publication Number Publication Date
TW202144007A true TW202144007A (zh) 2021-12-01

Family

ID=78023849

Family Applications (1)

Application Number Title Priority Date Filing Date
TW110112949A TW202144007A (zh) 2020-04-10 2021-04-09 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途

Country Status (3)

Country Link
CN (1) CN115279405A (fr)
TW (1) TW202144007A (fr)
WO (1) WO2021203769A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101676267B (zh) * 2008-09-16 2012-12-26 江苏恒瑞医药股份有限公司 N-[4-(1-氰基环戊基)苯基]-2-(4-吡啶甲基)氨基-3-吡啶甲酰胺的盐
EA035037B1 (ru) * 2013-12-12 2020-04-21 Шанхай Хэнжуй Фармасьютикал Ко., Лтд. Антитело к pd-1, его антигенсвязывающий фрагмент и их медицинское применение
CN106999591B (zh) * 2015-09-28 2021-02-23 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体制剂及其在医药上的应用
TWI764943B (zh) * 2016-10-10 2022-05-21 大陸商蘇州盛迪亞生物醫藥有限公司 一種抗pd-1抗體和vegfr抑制劑聯合在製備治療癌症的藥物中的用途
CN108079292A (zh) * 2016-11-23 2018-05-29 苏州盛迪亚生物医药有限公司 一种抗pd-1抗体在制备治疗肝癌的药物中的用途
CN106963948A (zh) * 2017-05-12 2017-07-21 顾艳宏 阿帕替尼与Anti‑PD‑1抗体联用在制备结肠癌药物中的应用

Also Published As

Publication number Publication date
WO2021203769A1 (fr) 2021-10-14
CN115279405A (zh) 2022-11-01

Similar Documents

Publication Publication Date Title
RU2762746C2 (ru) Применение комбинации антитела к pd-1 и ингибитора vegfr в изготовлении лекарственного средства для лечения злокачественных новообразований
CN111065411B (zh) Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途
CN112007162B (zh) Ezh2抑制剂与免疫检查点抑制剂、vegfr抑制剂联合在制备治疗肿瘤药物中的用途
CA3133141A1 (fr) Composition pharmaceutique combinee pour le traitement du cancer du poumon a petites cellules
WO2021063340A1 (fr) Utilisation d'un inhibiteur d'ezh2 en association avec un inhibiteur de point de contrôle immunitaire et un inhibiteur de tyrosine kinase dans la préparation d'un médicament pour le traitement d'une tumeur
CN112168961A (zh) 治疗结直肠癌的联用药物组合物
CN112512580B (zh) Ezh2抑制剂与免疫检查点抑制剂联合在制备治疗肿瘤的药物中的用途
WO2020239085A1 (fr) Composition pharmaceutique combinée pour le traitement du mélanome
CN112955148B (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗淋巴瘤的药物中的用途
CN110859959A (zh) 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途
WO2021057764A1 (fr) Utilisation d'un anticorps pd-1 en combinaison avec un composé taxoïde dans la préparation de médicaments pour le traitement du cancer du sein triple-négatif
TW202144007A (zh) 一種抗ｐｄ－１抗體在製備治療肢端黑色素瘤的藥物中的用途
CN113491769A (zh) 药物联合
CN110680919A (zh) Cdk4/6抑制剂联合免疫治疗在制备治疗肿瘤的药物的用途
CN110812485A (zh) 抗pd-1抗体联合化学疗法在制备治疗肿瘤的药物中的用途
TWI822897B (zh) 一種抗pd-1抗體和法米替尼聯合在製備治療腫瘤的藥物中的用途
WO2023174408A1 (fr) Combinaison pharmaceutique d'anticorps anti-tim-3 et d'anticorps anti-pd-l1
CN114099670A (zh) 酪氨酸激酶抑制剂与抗pd-1抗体联合在制备治疗肿瘤药物中的用途
KR20240046526A (ko) 소세포폐암 치료용 약학적 조성물
TW202330040A (zh) 抗ｈｅｒ２抗體藥物偶聯物和酪胺酸激酶抑制劑聯合在製備治療腫瘤的藥物中的用途
CN117085123A (zh) 抗PD-L1抗体和c-Met激酶抑制剂的药物组合
CN113993544A (zh) 用于治疗egfr高表达的癌症的多变剂量方法